A B S T R A C T We have previously shown that flow cytometric analysis of acridine orange-stained bone marrow cells is useful for the objective enumeration and characterization of plasma cells from patients with myeloma, frequently exhibiting an abnormal DNA and an elevated RNA content. In this report on 77 previously untreated patients, we have investigated the biologic and prognostic implications of these quantitative tumor cell parameters. The degree of marrow involvement by tumor, both by microscopic and cytometric analysis, correlated with the clinically derived tumor mass stage. Examination of the product of relative tumor cell RNA content and marrow tumor infiltrate (as a measure of metabolic capacity for immunoglobulin production) in relationship to the myeloma protein concentration in the serum revealed differences in the efficiency of immunoglobulin production and/or catabolism. There was an inverse relationship between the degree of marrow tumor involvement and RNA index, suggesting a more aggressive behavior of myeloma in patients with a low tumor cell RNA content. Prognostically, high tumor cell RNA content identified patients with a high likelihood of response to both initial treatment (32 patients, P = 0.004) and salvage therapy (29 patients, P = 0.01). Favorable factors for survival were low clinical tumor mass stage (P = 0.07) and low marrow tumor infiltrate as determined morphologically (P = 0.04) and cytometrically (P = 0.004). Thus, the direct examination of marrow cellular DNA and RNA content permitted assessment of tumor burden and was useful in the prediction of response and survival.
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Tumor cytoreduction by .75% has been observed in about one-half of patients treated with alkylating agent-prednisone combinations (6, 7) . Unfortunately, no clinical or laboratory feature has consistently predicted response. Hofmann et al. (8) recently reported on the usefulness of tritiated thymidine grain count evaluation to predict both response and survival in myeloma patients, but the procedure is laborious and relies on microscopic identification of myeloma tumor cells after autoradiographic processing.
We have previously demonstrated that cytometry of DNA and RNA content is an objective means to quantitate tumor cells in the marrow of the majority of patients with myeloma, as well as in about one-half of patients with benign monoclonal gammopathy (5, 9, 10 (Table I) (1) . Treatment consisted of intermittent courses of vincristine, cyclophosphamide, adriamycin, and prednisone, according to standard treatment protocols (12 In addition, we have also evaluated 29 patients with refractory myeloma, who were treated with a combination of vinca alkaloids, adriamycin, and high dose prednisone (13) .
In all patients, marrow aspirates from the posterior iliac crest were obtained under local anesthesia. Smears (14) . In 34 patients, we performed FCM analysis of both DNA and RNA content. This involved staining of unfixed cells with acridine orange, according to the twostep procedure reported by Traganos et al. (15) . FCM analysis was performed with an ICP flow cytometer (Phywe, Gottingen, FRG) using filter combinations described previously (16 and/or DNA content. These determinations were accomplished with the use of a "boxogram" gating procedure (10) .
Statistical analyses included the following: comparisons of response rates among groups using chi-square tests (17) ; tests for linear trend in response rates (16) ; various standard tests of correlation and regression; and a modified Wilcoxon test for differences in survival distributions (18) .
RESULTS
Cytometry-derived measurements and marrow plasmacytosis. Representative examples of bone marrow DNA-RNA histograms of a case each of hyperdiploid and diploid myeloma are depicted in Fig. 1 . As verified by in vitro mixing experiments with peripheral blood from normal donors (data not shown; 9, 10), myeloma tumor cells, in both instances, are characterized by a significantly higher RNA content than residual normal marrow cells. The discrimination between tumor and normal cells is further enhanced 'Abbreviations used in this paper: DI, DNA index; FCM analysis, flow cytometric analysis; RI, RNA index; RRI, relative RI. in the case of an additional abnormality in DNA content ( Fig. 1 B) .
Abnormalities in DNA content were present in 79% of 77 patients, with a median DI of 1.1 (range 0.9 to 1.9). A distinctly elevated RNA content was noted in all 34 patients in whom acridine orange measurements were performed. The median RI was 4.9 (range 1.1 to 17.3). The detection rate by DNA analysis in this group was 80% and hence similar to our experience in the larger patient sample. Thus, analysis of RNA content using acridine orange in this study population enhances the cytometric detection rate of myeloma tumor cells to 100%. There was a linear correlation between the degree of marrow plasmacytosis and the proportion of tumor cells in the marrow as identified by either cytometric technique ( Fig. 2 ; r = 0.75, P < 0.001).
Marrow tumor infiltrate and clinical tumor mass stage. Fig. 3 depicts a comparison between the proportions of microscopically and cytometrically defined marrow tumor cells as a function of clinical tumor mass stage. With increasing tumor mass, there was evidence of a linear increase in the proportion of both microscopically recognized plasma cells (P = 0.01) and of cytometrically abnormal cells, both as measured by DNA (P < 0.01) or DNA and RNA (P < 0.01).
RI, marrow tumor infiltrate, and M-protein concentration. For the subgroup of 34 patients with available DNA/RNA FCM measurements, we analyzed the relationship between marrow tumor infiltrate and RI. Excluding two patients with exceptionally high RI values, >12, an inverse relationship be- tween these two parameters was noted, i.e., RI decreased with increasing marrow tumor infiltrate (r --0.24; P = 0.08). Fig. 4 examines the product of RI and the percentage of cytometrically identifiable tumor cells (as a measure of the capacity for protein synthesis) in relationship to serum M-protein concentration. For 16 of 26 patients, there was strong evidence that this product increased linearly with serum M-protein concentration (r = 0.6; P = 0.01). There were 10 individuals including 1 patient with nonsecretory disease in whom, for a given M-protein concentration, the cellular metabolic capacity was considerably higher than in the previous group, suggesting ineffective immunoglobulin secretion. 6 of these 10 patients had a high tumor mass stage compared with 6 of 16 in the aforementioned group. (Table II) , did not affect survival, when analyzed in the specified two evenly distributed subgroups with values below and above 5 (Fig. 6 d) . However, the derived RRI parameter separated, as did FCM-defined marrow tumor infiltrate (c), good and poor survival risk groups (Fig. 6 e, P = 0.004). DISCUSSION The present investigation confirms our earlier reports on the usefulness of FCM analysis to objectively enumerate myeloma tumor cells in heterogeneous bone marrow (5, 9, 10) . In addition, we demonstrate biological and clinical implications of bone marrow tumor infiltrate using both standard morphologic and cytometric means. Thus, the proportional increase in marrow tumor infiltrate with increasing tumor mass stage indicates the usefulness of the widely neglected plasma cell differential for the direct definition of tumor mass grade. This was further supported by the prognostic association also of plasmacytosis with survival. Analysis of the difference between marrow plasmacytosis and cytometry-derived measurements of marrow tumor infiltrate revealed that for 85% of all patients, the dif- Of interest was the correlation between immunoglobulin production capacity, as assessed by the product of RI and marrow tumor infiltrate, and serum Mprotein concentration. There was a subgroup of )' all patients with this particular characteristic.
)I patients with DNA FCM abnormal cells, i.e., patients who displayed, for a given M-protein concentration, an inappropriately high tumor metabolic capacity, the extreme being represented by patients with nonsecretory myeloma (20) . Such ineffective immunoglobulin production is consistent with the occurrence of premature immunoglobulin catabolism both intracellularly and extracellularly in some patients. One of our salient observations consists of the prognostic implications of the cellular features of myeloma derived from one single marrow examination. Thus, tumor cell RI and RRI were associated with remission induction, whereas the cytometrically defined marrow tumor infiltrate and RRI, but not RI by itself, correlated with survival. Hence, although the same derived FCM parameter (RRI) affected both short-and longterm prognosis, the tumor cell intrinsic RI seemed to impact on remission induction (in both untreated and refractory myeloma), and the tumor burden-related marrow tumor infiltrate predominantly determined survival. The present study group is too small to assess whether the survival implications of the FCM analysisderived pretreatment variables apply both in responding patients and in the treatment failure group. The greater sensitivity to chemotherapy of myeloma preexcluding diploid disease.
senting with high RI (suggesting a higher degree of tumor differentiation) and low tumor mass is poorly understood. We do not have evidence for a cytokinetic mechanism, such as higher growth fraction in the presence of low tumor burden, favoring chemotherapy sensitivity. In fact, data by Hofmann et al. (8) on thymidine grain count would suggest that myeloma with low DNA synthetic activity is more responsive to induction chemotherapy. This observation is compatible with our results, if one assumes that more differentiated myeloma with high RI is characterized by lower proliferative activity. A superior chemotherapy response in low compared with high proliferative activity tumors does not fit conventional concepts of cell kinetics. The higher response rate in high RI and low tumor burden myeloma may reflect a smaller proportion of drug-resistant cell subpopulations as recently suggested by Goldie et al. (21) . Research is ongoing in our laboratory to determine the interrelationship between tumor cell RI, cytokinetics, and tumor mass stage, in an effort to further define the predictive power of pretreatment cellular measurements. The development of prognostic models for incidence and duration of remission and for survival should enable OA!1t uoiliodoJd us to investigate new agents in high risk patients during various phases of their disease, as has been successfully done in adult acute leukemia (22, 23) .
